Company profile
U.S. Stem Cell, Inc.
OTC: USRM · Healthcare · Biotechnology
#1055 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 47GM —SS 41
v0.1 · 25/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$82.0k
Rev growth YoY (TTM)
-59.1%
Net income (FY)
-$2.9M
Employees
11
as of 2026-08-28
Market cap
$64.2k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$82.0k$82.0k2022
Net income-$2.9M-$2.9M2022
Operating income-$1.7M-$1.7M2022
Total assets$68.0k$68.0k2022
Liabilities$14.8M$14.8M2022
Equity-$14.7M-$14.7M2022
Revenue trend
FY2018 – FY2022 · USD
FY18
FY16
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Product81%
Service19%
By geography
Not disclosed.
The read
What is U.S. Stem Cell, Inc.’s revenue?
U.S. Stem Cell, Inc. booked $82.0k in FY2022 revenue, contracting 59% year over year — slower than 84% of Healthcare companies we track, at a -3483.2% net margin.
Peers · Healthcare
AIM ImmunoTech Inc.36DZecotek Photonics Inc.——Black Bird Biotech, Inc.——Sera Prognostics, Inc.41DXebra Brands Ltd.——Imaging Dynamics Company Ltd.31DNeighbors
Broward →Key facts
CEOMichael Tomas
SectorHealthcare
IndustryBiotechnology
HeadquartersSunrise, FL
ExchangeOTC: USRM
Employees11
IPO date2008-02-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.